nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Amanitins and their development as a payload for antibody-drug conjugates
|
Pahl, Andreas |
|
2018 |
30 |
C |
p. 85-89 |
artikel |
2 |
Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy
|
Johnston, Michael C. |
|
2018 |
30 |
C |
p. 63-69 |
artikel |
3 |
Antibody – Drug conjugates (ADC) – Drug discovery today: Technologies
|
Chudasama, Vijay |
|
2018 |
30 |
C |
p. 1-2 |
artikel |
4 |
Bispecifics and antibody–drug conjugates: A positive synergy
|
Maruani, Antoine |
|
2018 |
30 |
C |
p. 55-61 |
artikel |
5 |
Drawing lessons from the clinical development of antibody-drug conjugates
|
Lyon, Robert |
|
2018 |
30 |
C |
p. 105-109 |
artikel |
6 |
Enzymatic strategies for (near) clinical development of antibody-drug conjugates
|
van Berkel, Sander S. |
|
2018 |
30 |
C |
p. 3-10 |
artikel |
7 |
Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery
|
Richards, Daniel A. |
|
2018 |
30 |
C |
p. 35-46 |
artikel |
8 |
Homogeneous antibody-drug conjugates via site-selective disulfide bridging
|
Forte, Nafsika |
|
2018 |
30 |
C |
p. 11-20 |
artikel |
9 |
Miniaturised ‘antibody’-drug conjugates for solid tumours?
|
Deonarain, Mahendra P. |
|
2018 |
30 |
C |
p. 47-53 |
artikel |
10 |
Minireview: Addressing the retro-Michael instability of maleimide bioconjugates
|
Szijj, Peter A. |
|
2018 |
30 |
C |
p. 27-34 |
artikel |
11 |
Recent, non-classical, approaches to antibody lysine modification
|
Chaubet, Guilhem |
|
2018 |
30 |
C |
p. 21-26 |
artikel |
12 |
Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals
|
Morais, Mauricio |
|
2018 |
30 |
C |
p. 91-104 |
artikel |
13 |
Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?
|
Jackson, Paul J.M. |
|
2018 |
30 |
C |
p. 71-83 |
artikel |